ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Positive results in Duchenne muscular dystrophy (DMD) trial
October 09, 2020Interim trial results suggest vamorolone may offer a superior alternative to long-term treatment with high-dose glucocorticoids in young Duchenne muscular dystrophy (DMD) patients. -
Santhera to Obtain Worldwide Rights to Vamorolone
September 07, 2020Santhera Pharmaceuticals has signed agreements with Idorsia and ReveraGen BioPharma, making Santhera a direct license holder of vamorolone. -
Santhera obtains exclusive licence to DMD drug vamorolone
September 04, 2020Santhera Pharmaceuticals has entered agreements with Idorsia and ReveraGen BioPharma to gain exclusive global rights to Duchenne muscular dystrophy (DMD) drug, called vamorolone.
Pharma Sources Insight January 2025
